Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes-Reference-Cited by-同舟云学术

Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes

Published:2016-11-21 Issue:1 Volume:60 Page:3-6
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Funder

University of Sheffield

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-016-4146-6.pdf

Reference24 articles.

1. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988) Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37:901–907

2. Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE (1988) Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in non-diabetics. N Engl J Med 318:1487–1492

3. Heller SR, Cryer PE (1991) Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 40:223–226

4. Dagogo-Jack S, Craft S, Cryer PE (1993) Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819–828

5. Cryer PE (2013) Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 369:362–372

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BaTiO3 Boosted Silver-based SPR Sensor for Efficient Urine-glucose Detection in Pre-diabetic and Early Diabetic Stages;Sensors and Actuators A: Physical;2024-09

2. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial;Diabetes, Obesity and Metabolism;2024-08-27

3. Clinical evidence for high‐risk CE‐marked medical devices for glucose management: A systematic review and meta‐analysis;Diabetes, Obesity and Metabolism;2024-08-14

4. A Scalable Application of Artificial Intelligence-Driven Insulin Titration Program to Transform Type 2 Diabetes Management;Diabetes Technology & Therapeutics;2024-08-01

5. Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study;Diabetes, Obesity and Metabolism;2024-07-29